Nightstar Therapeutics Financials

Net income (H1, 2017)(7.7 M)
EBIT (H1, 2017)(7.7 M)
Cash, 30-Jun-201769.6 M

Revenue/Financials

Income Statement

Annual

USDFY, 2015FY, 2016

R&D expense

7.2 m10.2 m

General and administrative expense

2.1 m2.1 m

Operating expense total

9.3 m12.2 m

EBIT

(9.3 m)(12.2 m)

Interest income

9 k22 k

Net Income

(13.6 m)(12.2 m)

    Half Year

    USDH1, 2016H1, 2017

    R&D expense

    5.1 m6.3 m

    General and administrative expense

    812 k1.4 m

    Operating expense total

    5.9 m7.7 m

    EBIT

    (5.9 m)(7.7 m)

    Interest income

    21 k6 k

    Net Income

    (5.9 m)(7.7 m)

      Balance Sheet

      Annual

      USDFY, 2015FY, 2016

      Cash

      10.7 m10.1 m

      Prepaid Expenses

      3.1 m4.1 m

      Current Assets

      13.8 m14.2 m

      PP&E

      253 k363 k

      Total Assets

      14.1 m14.6 m

      Accounts Payable

      1 m1.2 m

      Current Liabilities

      3 m5.6 m

      Total Liabilities

      3 m5.6 m

      Additional Paid-in Capital

      32 m43.5 m

      Retained Earnings

      (20.1 m)(32.3 m)

      Total Equity

      11.1 m9 m

      Financial Leverage

      1.3 x1.6 x

      Half Year

      USDH1, 2017

      Cash

      69.6 m

      Prepaid Expenses

      6.5 m

      Current Assets

      76.1 m

      PP&E

      342 k

      Total Assets

      76.4 m

      Accounts Payable

      3 m

      Current Liabilities

      9.7 m

      Total Liabilities

      9.7 m

      Common Stock

      1 k

      Additional Paid-in Capital

      107.1 m

      Retained Earnings

      (40 m)

      Total Equity

      66.7 m

      Financial Leverage

      1.1 x

      Cash Flow

      Annual

      USDFY, 2015FY, 2016

      Net Income

      (13.6 m)(12.2 m)

      Depreciation and Amortization

      40 k138 k

      Accounts Payable

      384 k419 k

      Cash From Operating Activities

      (9.7 m)(10.1 m)

      Purchases of PP&E

      (289 k)(306 k)

      Cash From Investing Activities

      (289 k)(306 k)

      Cash From Financing Activities

      14 m11.3 m

      Net Change in Cash

      3.5 m(554 k)

      Half Year

      USDH1, 2016H1, 2017

      Net Income

      (5.9 m)(7.7 m)

      Depreciation and Amortization

      51 k95 k

      Accounts Payable

      91 k1.7 m

      Cash From Operating Activities

      (5.9 m)(5.7 m)

      Purchases of PP&E

      (186 k)(55 k)

      Cash From Investing Activities

      (186 k)(55 k)

      Cash From Financing Activities

      63.4 m

      Net Change in Cash

      (6.8 m)59.5 m

      Ratios

      Y, 2017

      Financial Leverage

      1.1 x